menu
    • menu
    [{"orgOrder":0,"company":"Zag Bio","sponsor":"T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Series A Financing","leadProduct":"ZAG-101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Zag Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Zag Bio \/ T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital","highestDevelopmentStatusID":"4","companyTruncated":"Zag Bio \/ T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Zag Bio

    Menu

    Zag Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Zag Bio

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed

                            Zag Bio

                            U.S.A arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZAG-101

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Zag Bio™ Launches with $80M to Advance Thymus-targeted Medicines for Autoimmune Diseases

                            Details : The Series A financing for ZAG-101, an unconjugated antibody targeting Type 1 diabetes, will advance research in this key focus area.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 28, 2025

                            Lead Product(s) : ZAG-101

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : T1D Fund | Polaris Partners | Mission BioCapital | AbbVie Ventures | Sanofi Ventures | Regeneron Ventures | Boxer Capital

                            Deal Size : $80.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth